406 related articles for article (PubMed ID: 18416765)
1. Allergic contact dermatitis due to transdermal buprenorphine.
Pérez-Pérez L; Cabanillas M; Loureiro M; Fernández-Redondo V; Labandeira J; Toribio J
Contact Dermatitis; 2008 May; 58(5):310-2. PubMed ID: 18416765
[No Abstract] [Full Text] [Related]
2. Allergic contact dermatitis from transdermal buprenorphine.
Vander Hulst K; Parera Amer E; Jacobs C; Dewulf V; Baeck M; Pujol Vallverdú RM; Giménez-Arnau A; Tennstedt D; Goossens A
Contact Dermatitis; 2008 Dec; 59(6):366-9. PubMed ID: 19076888
[TBL] [Abstract][Full Text] [Related]
3. Allergic contact dermatitis from buprenorphine.
Callejo Melgosa AM; Martínez JC; Fuentes MJ; Martín C
Allergy; 2005 Sep; 60(9):1217-8. PubMed ID: 16076316
[No Abstract] [Full Text] [Related]
4. Allergic contact dermatitis caused by transdermal buprenorphine.
Kyrklund C; Hyry H; Alanko K
Contact Dermatitis; 2013 Jul; 69(1):60-1. PubMed ID: 23782362
[No Abstract] [Full Text] [Related]
5. [Systemic reactivation of contact eczema following tramadol administration in a patient with buprenorphine-induced eczema].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2012 Apr; 139(4):335-6. PubMed ID: 22482491
[No Abstract] [Full Text] [Related]
6. Contact dermatitis from estradiol in a transdermal therapeutic system.
Panhans-Gross A; Gall H; Dziuk M; Peter RU
Contact Dermatitis; 2000 Dec; 43(6):368-9. PubMed ID: 11140397
[No Abstract] [Full Text] [Related]
7. Systemic contact dermatitis following oral exposure to tramadol in a patient with allergic contact dermatitis caused by buprenorphine.
Kaae J; Menné T; Thyssen JP
Contact Dermatitis; 2012 Feb; 66(2):106-7. PubMed ID: 22233471
[No Abstract] [Full Text] [Related]
8. Allergic contact dermatitis from buprenorphine and oral tolerance to other opioid derivatives in three patients.
Huilaja L; Riekki R; Immonen A; Tasanen K
Dermatology; 2014; 228(2):130-1. PubMed ID: 24280659
[TBL] [Abstract][Full Text] [Related]
9. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
Tschirner M; Ritzdorf I; Brünjes R
MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
[TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine (Butrans) for chronic pain.
Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936
[TBL] [Abstract][Full Text] [Related]
11. [Buprenorphine matrix patch well tolerated. The challenge of tumor pain].
MMW Fortschr Med; 2006 Jan; 148(1-2):42-3. PubMed ID: 16612846
[No Abstract] [Full Text] [Related]
12. Case of allergic contact dermatitis due to a topical agent containing chlorpheniramine maleate, with a false-negative patch test.
Ueno T; Kawana S
J Dermatol; 2008 Jan; 35(1):46-8. PubMed ID: 18181779
[No Abstract] [Full Text] [Related]
13. Systemic allergic contact dermatitis from intravenous piritramide.
Waltermann K; Geier J; Diessenbacher P; Schadendorf D; Hillen U
Allergy; 2010 Sep; 65(9):1203-4. PubMed ID: 20192944
[No Abstract] [Full Text] [Related]
14. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland.
Przeklasa-Muszynska A; Dobrogowski J
Curr Med Res Opin; 2011 Jun; 27(6):1109-17. PubMed ID: 21456888
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
[TBL] [Abstract][Full Text] [Related]
16. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
Barutell C; Camba A; González-Escalada JR; Rodríguez M;
Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
[TBL] [Abstract][Full Text] [Related]
17. [Transdermal buprenorphine and silent acute coronary syndrome].
Vidal MA; Calderón E; Pernia A; Calderón-Pla E; Torres LM
Rev Esp Anestesiol Reanim; 2006 Jan; 53(1):58-9. PubMed ID: 16475644
[No Abstract] [Full Text] [Related]
18. Buprenorphine TTS for children--a review of the drug's clinical pharmacology.
Michel E; Anderson BJ; Zernikow B
Paediatr Anaesth; 2011 Mar; 21(3):280-90. PubMed ID: 21091589
[TBL] [Abstract][Full Text] [Related]
19. Allergic contact dermatitis caused by tetracaine contained in otic drops.
García-Gavín J; Alonso-González J; Gutiérrez-González E; Álvarez-Pérez A; Fernández-Redondo V; Toribio J
Contact Dermatitis; 2011 Sep; 65(3):175-6. PubMed ID: 21827509
[No Abstract] [Full Text] [Related]
20. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
